AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Brevity of lessons
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low priority accorded to PSE by senior management
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' limited experience and ability in use of role‐play
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature of the adoption process
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff absence and turnover
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical understanding of the package
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to the research
Number of subjects: 13
Study 11079284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan tablets
Number of subjects: 0
Study 11079284 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 0
Study 8922196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C plus vindesine plus etoposide (MEV)
Number of subjects: 204
Study 8922196 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C plus vindesine plus cisplatin (MVP)
Number of subjects: 204
Study 1305042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain administered intramuscularly (i.m.) or intravenously (i.v.) every one, two or three days in doses of 5 to 50 mg for 7 to 40 days
Number of subjects: 19
Study 1305042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain administered for three years in the dose of 5 to 50 mg/injection in repeated courses
Number of subjects: 19
Study 4003139 — intervention group
Group type: EXPERIMENTAL
Intervention: Work periods (30, 60, and 120 minutes) during Experiment 2
Number of subjects: 0
Study 4003139 — intervention group
Group type: COMPARATOR
Intervention: Days with no work periods (control days)
Number of subjects: 0
Study 4003139 — intervention group
Group type: EXPERIMENTAL
Intervention: Work periods of varying lengths (30, 60, and 120 minutes)
Number of subjects: 0
Study 30872116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 78
Study 30872116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 28759833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment for 8 weeks
Number of subjects: 20
Study 28759833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25118333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet AL (PAL) intervention
Number of subjects: 40
Study 25118333 — intervention group
Group type: COMPARATOR
Intervention: Reminiscing intervention
Number of subjects: 40
Study 23764683 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (100 mg twice daily, n = 16)
Number of subjects: 30
Study 23764683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study 21840734 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal dose of fluvastatin (80 mg/day)
Number of subjects: 52
Study 21840734 — intervention group
Group type: COMPARATOR
Intervention: Titrated dosing of fluvastatin (starting at 20 mg/day)
Number of subjects: 52
Study 19640855 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programme consisting of three sessions weekly over 12 weeks (one educational session and two physical activity sessions).
Number of subjects: 921
Study 19640855 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programme
Number of subjects: 921
Study 19640855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 921
Study 16545704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular widening using distraction osteogenesis
Number of subjects: 15
Study 16545704 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal occlusion
Number of subjects: 15
Study 12810336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulator (VNS) implantation
Number of subjects: 6
Study 10701034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol
Number of subjects: 43
Study 10701034 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-administered midazolam
Number of subjects: 43
Study 8989196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (3.0 to 20 micrograms/kg/min)
Number of subjects: 19
Study 8989196 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 19
Study 8491010 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach to radiofrequency catheter ablation
Number of subjects: 50
Study 8491010 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach to radiofrequency catheter ablation
Number of subjects: 50
Study 8491010 — intervention group
Group type: COMPARATOR
Intervention: Alternative technique after initial failure
Number of subjects: 50
Study 8491010 — intervention group
Group type: COMPARATOR
Intervention: Anterior lesion
Number of subjects: 50
Study 8491010 — intervention group
Group type: COMPARATOR
Intervention: Posterior lesion
Number of subjects: 50
Study 3438646 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 30
Study 3438646 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 30
Study 3438646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29602140 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1838
Study 29602140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838
Study 29602140 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1838
Study 28606915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 2584
Study 28606915 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 concentrations
Number of subjects: 2584
Study 26121303 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up prevention services
Number of subjects: 79
Study 23830392 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 20
Study 23830392 — intervention group
Group type: COMPARATOR
Intervention: Non-treated dental pulp
Number of subjects: 20
Study 21035866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser peripheral iridotomy (LPI)
Number of subjects: 116
Study 21035866 — intervention group
Group type: COMPARATOR
Intervention: No laser (control)
Number of subjects: 116
Study 18299307 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine mixed with rapid-acting insulin analog, administered twice daily
Number of subjects: 42
Study 18299307 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) therapy with rapid-acting insulin analog, administered twice daily
Number of subjects: 42
Study 16781218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (ASA)
Number of subjects: 14000
Study 16781218 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 14000
Study 16781218 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 14000
Study 15010555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine during labour and neonatally
Number of subjects: 365
Study 15010555 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm (control)
Number of subjects: 365
Study 10730742 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-optical intubation stylet (VOIS)
Number of subjects: 40
Study 10730742 — intervention group
Group type: COMPARATOR
Intervention: Bullard laryngoscope (BL)
Number of subjects: 40
Study 9413662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0
Study 9413662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 7978599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IV naloxone
Number of subjects: 14
Study 7978599 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IV naloxone
Number of subjects: 14
Study 2689916 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil chlorhydrate (150 mg intravenous injection in bolus)
Number of subjects: 20
Study 2689916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4570905 — intervention group
Group type: COMPARATOR
Intervention: Phenoxybenzamine
Number of subjects: 10
Study 4570905 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 10
Study 30631062 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 30631062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28457714 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program aimed at discouraging sugar-sweetened carbonated beverages intake
Number of subjects: 478
Study 28457714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 478
Study 25219982 — intervention group
Group type: EXPERIMENTAL
Intervention: Retina Implant Alpha IMS
Number of subjects: 9
Study 23860295 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β2‐agonist (SABA) - 20 µg of inhaled procaterol
Number of subjects: 10
Study 23860295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22103957 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (MINT)
Number of subjects: 106
Study 22103957 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 106
Study 19398092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol and 400 mg progesterone
Number of subjects: 27
Study 19398092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol and 400 mg progesterone
Number of subjects: 27
Study 19398092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol and placebo
Number of subjects: 27
Study 17301636 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation and exercise information
Number of subjects: 70
Study 17301636 — intervention group
Group type: COMPARATOR
Intervention: Exercise information only (Control)
Number of subjects: 70
Study 15148494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM)
Number of subjects: 184
Study 15148494 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Blood Progenitor Cells (PBPC)
Number of subjects: 184
Study 12413372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab and half-dose reteplase)
Number of subjects: 16453
Study 12413372 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of reteplase
Number of subjects: 16453
Study 12413372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16453
Study 9844098 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (30-minute sessions of weight-bearing physical education lessons three times weekly for 8 months)
Number of subjects: 20
Study 9844098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 7536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for cystic fibrosis, details on dosage and duration not available
Number of subjects: 0
Study 7536619 — intervention group
Group type: COMPARATOR
Intervention: Current treatments for cystic fibrosis, details on specific treatments not available
Number of subjects: 0
Study 1976339 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg twice a day)
Number of subjects: 14
Study 1976339 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 6993253 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard inhaler
Number of subjects: 0
Study 6993253 — intervention group
Group type: COMPARATOR
Intervention: Inhaler with a 32 X 100 mm tube actuated 2 seconds before inhalation
Number of subjects: 0
Study 29890899 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute acute bout of treadmill walking (N=25)
Number of subjects: 51
Study 29890899 — intervention group
Group type: COMPARATOR
Intervention: 15 minutes of sitting (Control group; N=26)
Number of subjects: 51
Study 28835058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg intravenously after general anesthesia induction
Number of subjects: 80
Study 28835058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream with endotracheal tube
Number of subjects: 80
Study 28835058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexmedetomidine with lidocaine cream
Number of subjects: 80
Study 28835058 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline and liquid paraffin)
Number of subjects: 80
Study 25936655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized interpretation training
Number of subjects: 72
Study 25936655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 72
Study 25936655 — intervention group
Group type: COMPARATOR
Intervention: Active placebo control
Number of subjects: 72
Study 23435568 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 314
Study 23435568 — intervention group
Group type: COMPARATOR
Intervention: WGL
Number of subjects: 314
Study 21425738 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with flexible stick training (EF group)
Number of subjects: 30
Study 21425738 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi training (TC group)
Number of subjects: 30
Study 19246310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.6‐1.8 mg) plus tropisetron (5 mg/100 ml)
Number of subjects: 140
Study 19246310 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.8‐1.0 mg) and flurbiprofen axetil (200 mg) plus tropisetron (5 mg/100 ml)
Number of subjects: 140
Study 19246310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 16551898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg)
Number of subjects: 90
Study 16551898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg)
Number of subjects: 90
Study 16551898 — intervention group
Group type: COMPARATOR
Intervention: Saline (S-group)
Number of subjects: 90
Study 14631327 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin 1000 mg twice a day
Number of subjects: 12
Study 14631327 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 12
Study 10847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone cream 40 mg daily
Number of subjects: 24
Study 10847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone cream 20 mg, twice daily
Number of subjects: 24
Study 10847226 — intervention group
Group type: COMPARATOR
Intervention: Progesterone cream (both regimens)
Number of subjects: 24
Study 2065637 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement (22.5 mg daily)
Number of subjects: 56
Study 2065637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6343572 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin with usual medical therapy
Number of subjects: 421
Study 6343572 — intervention group
Group type: COMPARATOR
Intervention: Placebo with usual medical therapy
Number of subjects: 421
Study 6343572 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin only if usual therapy failed (strategy 2)
Number of subjects: 421
Study 6343572 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin with initial medical therapy (strategy 1)
Number of subjects: 421
Study 6343572 — intervention group
Group type: EXPERIMENTAL
Intervention: No indomethacin with surgery as backup (strategy 3)
Number of subjects: 421
Study 31109481 — intervention group
Group type: EXPERIMENTAL
Intervention: LE BID + qD bromfenac
Number of subjects: 100
Study 31109481 — intervention group
Group type: COMPARATOR
Intervention: LE QID + qD bromfenac (control group)
Number of subjects: 100
Study 29886215 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 46
Study 29886215 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic Bypass (BSX)
Number of subjects: 46
Study 27216875 — intervention group
Group type: EXPERIMENTAL
Intervention: High implementation of STEPs
Number of subjects: 20
Study 27216875 — intervention group
Group type: COMPARATOR
Intervention: Low implementation of STEPs
Number of subjects: 20
Study 23048018 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPX)
Number of subjects: 19
Study 23048018 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 19
Study 23048018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22564009 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet eye training
Number of subjects: 40
Study 22564009 — intervention group
Group type: COMPARATOR
Intervention: Technical training
Number of subjects: 40
Study 20237953 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory feedback (RFB)
Number of subjects: 42
Study 20237953 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent respiratory feedback (placebo)
Number of subjects: 42
Study 20237953 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB
Number of subjects: 42
Study 18024579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 73
Study 18024579 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 73
Study 16038246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mw vaccine (1 x 10^9 heat killed bacilli for the first dose, 5 x 10^8 for the second dose, given 6 months apart)
Number of subjects: 24060
Study 16038246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mw vaccine (when both patients and contacts received the vaccine)
Number of subjects: 24060
Study 16038246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mw vaccine (when only patients received the vaccine)
Number of subjects: 24060
Study 16038246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1/8th dose of normal dose of tetanus toxoid)
Number of subjects: 24060
Study 11929147 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-fit regression formula (CrExcr1)
Number of subjects: 885
Study 11929147 — intervention group
Group type: COMPARATOR
Intervention: Cockroft-Gault formula (CrExcr2)
Number of subjects: 885
Study 11929147 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured creatinine excretion (CrExcr)
Number of subjects: 885
Study 10336576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban 2 mg
Number of subjects: 4
Study 10336576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban 5-12 mg
Number of subjects: 4
Study 10336576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban 5-7 mg
Number of subjects: 4
Study 10336576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban 12 mg
Number of subjects: 4
Study 7482386 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg (BZ 10)
Number of subjects: 71
Study 7482386 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 5 mg/hydrochlorothiazide 6.25 mg (BZ + HCTZ)
Number of subjects: 71
Study 7482386 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 71
Study 1963134 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drugs for reducing occlusion frequency after coronary artery bypass
Number of subjects: 0
Study 1963134 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis using logistic regression
Number of subjects: 0
Study 6440658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 4.8 g with probenecid 1 g
Number of subjects: 63
Study 6440658 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 3 g with probenecid 1 g
Number of subjects: 63
Study 6440658 — intervention group
Group type: EXPERIMENTAL
Intervention: N meningitidis isolated from the pharynx
Number of subjects: 63
Study 31368282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen needling combined with swallowing training
Number of subjects: 100
Study 31368282 — intervention group
Group type: COMPARATOR
Intervention: Routine swallowing training
Number of subjects: 100
Study 29077584 — intervention group
Group type: EXPERIMENTAL
Intervention: delefilcon A
Number of subjects: 27
Study 29077584 — intervention group
Group type: EXPERIMENTAL
Intervention: narafilcon A
Number of subjects: 27
Study 29077584 — intervention group
Group type: EXPERIMENTAL
Intervention: omafilcon A
Number of subjects: 27
Study 29077584 — intervention group
Group type: EXPERIMENTAL
Intervention: nesofilcon A
Number of subjects: 27
Study 26809751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 911
Study 26809751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 24811543 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific fall prevention training program (six 30-minute sessions over 2 weeks)
Number of subjects: 14
Study 23513559 — intervention group
Group type: EXPERIMENTAL
Intervention: CLNP‐BPO5/TZ
Number of subjects: 40
Study 23513559 — intervention group
Group type: COMPARATOR
Intervention: CLNP‐BPO2.5/TZ
Number of subjects: 40
Study 21085635 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunization with Tat
Number of subjects: 87
Study 21085635 — intervention group
Group type: COMPARATOR
Intervention: Control group (observational study)
Number of subjects: 87
Study 18635912 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo (combination of ginseng, oriental bezoar, and glycyrrhiza)
Number of subjects: 10
Study 18635912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16847795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline while maintaining oxytocin infusion
Number of subjects: 29
Study 16847795 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin discontinuation
Number of subjects: 29
Study 16847795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline and oxytocin
Number of subjects: 29
Study 14565653 — intervention group
Group type: EXPERIMENTAL
Intervention: DVP (daunorubicin 45 mg/m2 daily, days 1, 2 and 3; prednisone 60 mg/m2 daily orally days 1‐35; vincristine 2 mg intravenously on days 1, 8, 15 and 22)
Number of subjects: 276